Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice

Infection and Immunity

Volumn 66, Issue 3, 1998, Pages 1057-1062

  Yuan, Rui Rong ^a   Spira, Gadi ^b   Oh, Jin ^a   Paizi, Melia ^b   Casadevall, Arturo ^a   Scharff, Matthew D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY; OPSONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; HUMORAL IMMUNITY; LUNG ALVEOLUS CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

EID: 1842601412     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.3.1057-1062.1998     Document Type: Article

References (45)

1. Briles, D. E., J. L. Claflin, K. Schroer, and C. Forman. 1981. Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature 294:88-90.
2. Casadevall, A. 1995. Antibody immunity and invasive fungal infections. Infect. Immun. 63:4211-4218.
3. Casadevall, A., J. Mukherjee, S. J. N. Devi, R. Schneerson, J. B. Robbins, and M. D. Scharff. 1992. Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 65:1086-1093.
4. Caulay, L. K., and J. W. Murphy. 1979. Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect. Immun. 23:644-651.
5. Chang, Y. C., and K. J. Kwon-Chung. 1994. Complementation of a capsule-deficient mutation of Ctyptococcus neoformans restores its virulence. Mol. Cell. Biol. 14:4912-4919.
6. Cherniak, R., and J. B. Sundstrom. 1994. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect. Immun. 62:1507-1512.
7. Currie, B. P., and A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City. Clin. Infect. Dis. 19:1029-1033.
8. Devi, S. J. N. 1996. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14:841-842.
9. Devi, S. J. N., R. Schneerson, W. Egan, T. J. Ulrich, D. Bryla, J. B. Robbins, and J. E. Bennett. 1991. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59:3700-3707.
10. Dong, Z. M., and J. W. Murphy. 1995. Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect. Immun. 63:2632-2644.
11. Dong, Z. M., and J. W. Murphy. 1996. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis receptor loss from the surface of human neutrophils. J. Clin. Invest. 97:689-698.
12. Dromer, F., J. Charreire, A. Contrepois, C. Carbon, and P. Yeni. 1987. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55:749-752.
13. Eckert, T. F., and T. R. Kozel. 1987. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55:1895-1899.
14. Feldmesser, M., and A. Casadevall. 1997. Effect of serum IgG1 against murine pulmonary infection with Cryptococcus neoformans. J. Immunol. 158: 790-799.
15. Goldman, D., S. C. Lee, and A. Casadevall. 1994. Pharmacokinetics of cryptococcal polysaccharide clearance. In Proceedings of the 34th International Conference of Antimicrobial Agents and Chemotherapy, Orlando, Fla. American Society for Microbiology. Washington, D.C.
16. Graybill, J. R., M. Hague, and D. LT. Drutz. 1981. Passive immunization in murine cryptococcosis. Sabouraudia 19:237-244.
17. Greenspan, N. S., D. A. Dacek, and L. J. Cooper. 1988. Fc region-dependence of IgG3 anti-streptococcal group A carbohydrate antibody functional affinity. I. The effect of temperature. J. Immunol. 141:4276-4282.
18. Griffin, F. M. 1980. Roles of macrophage Fc and C3b receptors in phagocytosis of immunologically coated Cryptococcus neoformans, Proc. Natl. Acad. Sci. USA 78:3853-3857.
19. Han, Y., and J. E. Cutler. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63:2714-2719.
20. Huffnagle, G. B., J. L. Yates, and M. F. Lipscomb. 1991. Immunity to pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J. Exp. Med. 173:793-800.
21. Kozel, T. R., G. S. T. Pfrommer, A. S. Guerlain, B. A. Highison, and G. J. Highison. 1988. Role of the capsule in phagocytosis of Cryptococcus neoformans. Rev. Infect. Dis. 10:S436-S439.
22. Levitz, S. M. 1991. The ecology of Cryptococcns neoformans and the epidemiology of cryptococcosis. Rev. Infect. Dis. 13:1163-1169.
23. Levitz, S. M., T. P. Farrell, and R. T. Maziarz. 1991. Killing of Cryptococcus neofonnans by human peripheral blood mononuclear cells stimulated in culture. J. Infect. Dis. 163:1108-1113.
24. Levitz, S. M., A. Tabumi, H. Kornfeld, C. C. Reardon, and D. T. Coleabock. 1994. Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans. Infect. Immun. 62:1975-1981.
25. Mitchell, T. G., and J. R. Perfect. 1995. Cryptococcosis in the era of AIDS -100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515-548.
26. Mody, C. H., M. F. Lipscomb, N. E. Street, and G. B. Toews. 1990. Depletion of CD4+ (L3T4+) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. J. Immunol. 144:1472-1477.
27. Mozaffarian, N., T. W. Berman, and A. Casadevall. 1995. Immune complexes increase nitric oxide production by interferon-gamma-stimulated murine macrophage-like J774.16 cells. J. Leukoc. Biol. 57:657-662.
28. Mukherjee, J., M. D. Scharff, and A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60:4534-4541.
29. Mukherjee, S., M. Feldmesser, and A. Casadevall. 1996. J774 Murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J. Infect. Dis. 173:1222-1231.
30. Mukherjee, S., S. C. Lee, and A. Casadevall. 1995. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63:573-579.
31. Murphy, J. A. 1991. Mechanisms of natural resistance to human pathogenic fungi. Annu. Rev. Microbiol. 45:509-538.
32. Nussbaum, G., R. Yuan, A. Casadevall, and M. D. Scharff. 1996. Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans. J. Exp. Med. 183:1905-1909.
33. Sanford, J. E., D. M. Lupan, A. M. Schlagetter, and T. R. Kozel. 1990. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysac-charide. Infect. Immun. 58:1919-1923.
34. Schlageter, A. M., and T. R. Kozel. 1990. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect. Immun. 58:1914-1918.
35. Spira, G., and M. D. Scharff. 1992. Identification of rare immunoglobulin switch variants using the ELISA spot assay. J. Immunol. Methods 148:121-129.
36. Spira, G., R. Yuan, M. Paizi, M. Weisendal, and A. Casadevall. 1994. Simultaneous expression of kappa and lambda light chains in a murine IgG3 anti-Cryptococcus neoformans hybridoma cell line. Hybridoma 13:531-535.
37. Valadon, P., G. Nussbaum, L. F. Boyd, D. H. Margulies, and M. D. Scharff. 1996. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. J. Mol. Biol. 261:11-22.
38. Vazcquez-Torres, A., J. Jones-Carson, and E. Balish. 1996. Peroxynitrite contributes to the candidacidal activity of nitric oxide-producing macrophages. Infect. Immun. 64:3127-3133.
39. Vecchiarelli, A., D. Pietrella, M. Dottorini, C. Monari, C. Retini, and T. Todisco. 1995. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin. Exp. Immunol. 98:217-223.
40. Vecchiarelli, A., C. Retini, C. Monari, C. Tascini, F. Bistoni, and T. R. Kozel. 1996. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect. Immun. 64:2846-2849.
41. Vecchiarelli, A., C. Retini, D. Pietrella, C. Monari, C. Tascini, T. Beacari, and T. R. Kozel. 1995. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect. Immun. 63:2919-2923.
42. Yuan, R., A. Casadevall, G. Spira, and M. D. Scharff. 1995. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J. Immunol. 154:1810-1816.
43. Yuan, R. R., A. Casadevall, J. Oh, and M. D. Scharff. 1997. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc. Natl. Acad. Sci. USA 94:2483-2488.
44. Zhong, Z., and L. Pirofski. 1996. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies. Infect. Immun. 64:3446-3450.
45. Zuger, A., E. Louie, R. S. Holzman, M. S. Simberkoff, and J. L. Rahal. 1986. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann. Intern. Med. 104:234-240.